	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	6870	epidermal adj growth adj factor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/14 16:29			0
2	BRS	L2	205	laminin adj receptor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/14 16:30			0
3	BRS	L3	0	((epidermal adj growth adj factor) same (modification or modified)) same ((laminin adj receptor) same (antagonist or agonist))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/14 16:30			0
4	BRS	L4	674	(epidermal adj growth adj factor) same (modification or modified)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/14 16:34			0
5	BRS	L6	68	tyrosine adj analog	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/14 16:32			0
6	BRS	L7	262	arginine adj analog	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/14 16:32			0
7	BRS	L8	0	4 same (6 or 7)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/14 16:32			0
8	BRS	L9	0	(epidermal adj growth adj factor) same (modification or modified) same retinopathy	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/14 16:33			0
9	BRS	L10	2	(laminin adj receptor) same (antagonist or agonist) same retinopathy	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/14 16:33			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
10	BRS	L11	25	(epidermal adj growth adj factor) same (modification or modified) same (endothelial adj cell)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/14 16:35			0
11	BRS	L12	1	11 same (wound or wounding)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/14 16:36			0

=> d his

(FILE 'HOME' ENTERED AT 16:39:06 ON 14 JUL 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
16:39:46 ON 14 JUL 2002
L1 130542 S EPIDERMAL GROWTH FACTOR
L2 3962 S L1 (P) MODIF?
L3 1932 S (TYROSINE ANALOG) OR (ARGININE ANALOG)
L4 3935 S LAMININ RECEPTOR
L5 52 S L4 (P) (ANGONIST OR ANTAGONIST)
L6 1 S L2 (P) L5
L7 2 S L2 (P) L3
L8 2 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)
L9 1 S L8 NOT L6
L10 68222 S RETINOPATHY
L11 0 S (ENDOTHLIAL CELL) (P) (WOUNDING OR WOUND)
L12 6 S L5 (P) L10
L13 2 DUPLICATE REMOVE L12 (4 DUPLICATES REMOVED)
L14 1 S L13 NOT (L8 OR L6)

=> log y

```
FILE 'HOME' ENTERED AT 16:39:06 ON 14 JUL 2002

=> file medline caplus biosis embase scisearch agricola
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21

FILE 'MEDLINE' ENTERED AT 16:39:46 ON 14 JUL 2002

FILE 'CAPLUS' ENTERED AT 16:39:46 ON 14 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:39:46 ON 14 JUL 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:39:46 ON 14 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V.  All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:39:46 ON 14 JUL 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 16:39:46 ON 14 JUL 2002

=> s epidermal growth factor
L1      130542 EPIDERMAL GROWTH FACTOR

=> s l1 (p) modif?
L2        3962 L1 (P) MODIF?

=> s (tyrosine analog) or (arginine analog)
L3        1932 (TYROSINE ANALOG) OR (ARGININE ANALOG)

=> s laminin receptor
L4        3935 LAMININ RECEPTOR

=> s l4 (p) (angonist or antagonist)
L5          52 L4 (P) (ANGONIST OR ANTAGONIST)

=> s l2 (p) l5
L6           1 L2 (P) L5

=> d l6 1 ibib abs

L6   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:        1999:691122  CAPLUS
DOCUMENT NUMBER:         131:295932
TITLE:                   Peptide fragments of murine epidermal growth factor as
                         laminin receptor targets for treatment of angiogenic
                         diseases
INVENTOR(S):             Nelson, John; Walker, Brian; McFerran, Neil; Harriott,
                         Patrick
PATENT ASSIGNEE(S):      The Queen's University of Belfast, UK
SOURCE:                  PCT Int. Appl., 35 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 9954356         A1   19991028       WO 1999-GB1211   19990421
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
             KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
             MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
             TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
```

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9936168 A1 19991108 AU 1999-36168 19990421
EP 1073679 A1 20010207 EP 1999-918126 19990421
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

PRIORITY APPLN. INFO.: GB 1998-8407 A 19980422
WO 1999-GB1211 W 19990421

AB The present invention provides the use of natural, synthetic or ***modified*** peptide factors derived from murine ***epidermal*** ***growth*** ***factor*** in the treatment of angiogenic diseases by targeting ***laminin*** ***receptors*** . The invention provides agonists and ***antagonists*** which may be ***modified*** to prevent proteolytic degrdn. Use of the invention to treat retinopathy of prematurity and promote wound healing is envisaged. The peptide factors of the invention are based on amino acid residues 33 to 42 of murine ***epidermal*** ***growth*** ***factor*** (mEGF). The amino acid sequence of mEGF-(33-42) is CVIGYSGDRC. Preferred substitutions include the use of tyrosine analogs at position 5 and arginine analogs at position 9. Preferably the peptide factor is capped at the N terminal with an acetyl group and at the C terminal with an amide group. Preferably the thiol groups of cysteines are capped with acetamido Me groups. The advantages of the invention, and the ways in which disadvantages of previously known arrangements are overcome include: (1) Unlike the native ***laminin*** ***receptor*** ligand (laminin.beta.-1925_933), which is angiogenic in human models, the mEGF33_42-derived agents are anti-angiogenic in human models, (2) mEGF33_42 has the advantage of inhibiting both laminin- and EGF-stimulated angiogenesis, and (3) mEGF33_42 prevents tumor cell attachment to basement membranes.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:39:06 ON 14 JUL 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:39:46 ON 14 JUL 2002

L1 130542 S EPIDERMAL GROWTH FACTOR
L2 3962 S L1 (P) MODIF?
L3 1932 S (TYROSINE ANALOG) OR (ARGININE ANALOG)
L4 3935 S LAMININ RECEPTOR
L5 52 S L4 (P) (ANGONIST OR ANTAGONIST)
L6 1 S L2 (P) L5

=> s l2 (p) l3
L7 2 L2 (P) L3

=> duplicate remove l7
PROCESSING COMPLETED FOR L7
L8 2 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)

=> s l8 not l6
L9 1 L8 NOT L6

=> d l9 1 ibib abs

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:294219 CAPLUS
Correction of: 2001:168136
DOCUMENT NUMBER: 134:337614
Correction of: 134:233606
TITLE: Nucleic acid-based ribozyme and DNAzyme modulators of gene expression
INVENTOR(S): McSwiggen, James; Usman, Nassim; Blatt, Lawrence; Beigelman, Leonid; Burgin, Alex; Karpeisky, Alexander; Matulic-adamic, Jasenka; Sweedler, David; Draper, Kenneth; Chowrira, Bharat; Stinchcomb, Dan; Beaudry, Amber; Zinnen, Shawn; Lugwig, Janos; Sproat, Brian S.

PATENT ASSIGNEE(S): Ribozyme Pharmaceuticals, Inc., USA
SOURCE: PCT Int Appl., 717 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016312 A2		20010308	WO 2000-US23998	20000830

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 1999-PV151713 19990831
US 1999-406643 19990927
US 1999-PV156467 19990927
US 1999-PV156236 19990927
US 1999-436430 19991108
US 1999-PV169100 19991206
US 1999-PV173612 19991229
US 1999-474432 19991229
US 1999-476387 19991230
US 2000-498824 20000204
US 2000-531025 20000320
US 2000-PV197769 20000414
US 2000-578223 20000523

AB Novel nucleic acid mols. useful as inhibitors of gene expression, compns., and methods for their use are provided. The invention features novel nucleic acid-based techniques (e.g., enzymic nucleic acid mols. (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, and antisense nucleic acids contg. RNA-cleaving chem. groups) and their use to modulate the expression of mol. targets impacting the development and progression of cancers, diabetes, obesity, Alzheimer's disease diseases, age-related diseases, and/or hepatitis B infections and related conditions. Catalytic nucleic acids were designed for site-specific cleavage of human mRNA targets encoding protein tyrosine phosphatase 1b, methionine aminopeptidase, .beta.-secretase, presenilin-1, epidermal growth factor receptor-2 (HER2/c-erb2/neu), phospholamban, telomerase, and hepatitis B virus genes. Methods for chem. synthesis of modified nucleoside triphosphates (NTPs) and RNA polymerase-catalyzed incorporation of modified NTPs into catalytic oligonucleotides are also provided. [This abstr. record os one of 6 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

=> d his

(FILE 'HOME' ENTERED AT 16:39:06 ON 14 JUL 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:39:46 ON 14 JUL 2002
L1 130542 S EPIDERMAL GROWTH FACTOR
L2 3962 S L1 (P) MODIF?
L3 1932 S (TYROSINE ANALOG) OR (ARGININE ANALOG)
L4 3935 S LAMININ RECEPTOR
L5 52 S L4 (P) (ANGONIST OR ANTAGONIST)
L6 1 S L2 (P) L5
L7 2 S L2 (P) L3
L8 2 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)
L9 1 S L8 NOT L6

=> s retinopathy
L10 68222 RETINOPATHY

=> s (endothlial cell) (p) (wounding or wound)
4 FILES SEARCHED...
L11 0 (ENDOTHLIAL CELL) (P) (WOUNDING OR WOUND)

```
=> s l5 (p) l10
L12          6 L5 (P) L10

=> duplicate remove l12
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L12
L13           2 DUPLICATE REMOVE L12 (4 DUPLICATES REMOVED)

=> s l13 not (l8 or l6)
L14          1 L13 NOT (L8 OR L6)

=> d l14 1 ibib abs

L14  ANSWER 1 OF 1     MEDLINE
ACCESSION NUMBER:   2002060506     MEDLINE
DOCUMENT NUMBER:    21645779   PubMed ID: 11786424
TITLE:              Synthetic peptides interacting with the 67-kd laminin
                    receptor can reduce retinal ischemia and inhibit
                    hypoxia-induced retinal neovascularization.
AUTHOR:             Gebarowska Dorota; Stitt Alan W; Gardiner Thomas A;
                    Harriott Patrick; Greer Brett; Nelson John
CORPORATE SOURCE:   Centre of Ophthalmology and Vision Science and the School
                    of Biology and Biochemistry, The Queen's University of
                    Belfast, Royal Victoria Hospital, Belfast, Northern
                    Ireland, United Kingdom.
SOURCE:             AMERICAN JOURNAL OF PATHOLOGY, (2002 Jan) 160 (1) 307-13.
                    Journal code: 0370502. ISSN: 0002-9440.
PUB. COUNTRY:       United States
                    Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:           English
FILE SEGMENT:       Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH:        200207
ENTRY DATE:         Entered STN: 20020125
                    Last Updated on STN: 20020707
                    Entered Medline: 20020705
AB   The high-affinity 67-kd   ***laminin***     ***receptor***   (67LR) is
     expressed by proliferating endothelial cells during retinal
     neovascularization. The role of 67LR has been further examined
     experimentally by administration of selective 67LR agonists and
       ***antagonists***   in a murine model of proliferative   ***retinopathy***
     . These synthetic 67LR ligands have been previously shown to stimulate or
     inhibit endothelial cell motility in vitro without any direct effect on
     proliferation. In the present study, a fluorescently labeled 67LR
       ***antagonist***   (EGF(33-42)) was injected intraperitoneally into mice
     and its distribution in the retina was assessed by confocal scanning laser
     microscopy. Within 2 hours this peptide was localized to the retinal
     vasculature, including preretinal neovascular complexes, and a significant
     amount had crossed the blood retinal barrier. For up to 24 hours
     postinjection, the peptide was still present in the retinal vascular walls
     and, to a lesser extent, in the neural retina. Non-labeled EGF(33-42)
     significantly inhibited pre-retinal neovascularization in comparison to
     controls treated with phosphate-buffered saline or scrambled peptide (P <
     0.0001). The agonist peptide (Lam beta 1(925-933)) also significantly
     inhibited proliferative   ***retinopathy***   ; however, it caused a
     concomitant reduction in retinal ischemia in this model by promoting
     significant revascularization of the central retina (P < 0.001). Thus,
     67LR appears to be an important target receptor for the modulation of
     retinal neovascularization. Agonism of this receptor may be valuable in
     reducing the hypoxia-stimulated release of angiogenic growth factors which
     drives retinal angiogenesis.


=> d his

     (FILE 'HOME' ENTERED AT 16:39:06 ON 14 JUL 2002)

     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
     16:39:46 ON 14 JUL 2002
L1        130542 S EPIDERMAL GROWTH FACTOR
L2          3962 S L1 (P) MODIF?
L3          1932 S (TYROSINE ANALOG) OR (ARGININE ANALOG)
```

```
L4          3935 S LAMININ RECEPTOR
L5            52 S L4 (P) (ANGON[redacted] OR ANTAGONIST)
L6             1 S L2 (P) L5
L7             2 S L2 (P) L3
L8             2 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)
L9             1 S L8 NOT L6
L10        68222 S RETINOPATHY
L11            0 S (ENDOTHLIAL CELL) (P) (WOUNDING OR WOUND)
L12            6 S L5 (P) L10
L13            2 DUPLICATE REMOVE L12 (4 DUPLICATES REMOVED)
L14            1 S L13 NOT (L8 OR L6)

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    42.61      42.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.24      -1.24

STN INTERNATIONAL LOGOFF AT 16:46:59 ON 14 JUL 2002
```